Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients
1/7/2008 8:31:22 AM
TAMPA, Fla.--(BUSINESS WIRE)--The following letter is from Dr. Francis E. O’Donnell, Jr., Chairman and Chief Executive Officer of Accentia Biopharmaceuticals (NASDAQ:ABPI). In addition to these comments, stockholders and potential investors are referred to: the Company’s SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports); press releases; website; and other publicly disseminated information, which is available free of charge upon request by contacting the Company.
comments powered by